Toward transcriptional therapies for the failing heart: Chemical screens to modulate genes

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 538-546

  McKinsey, Timothy A ^a   Olson, Eric N ^b  

^a Myogen Inc   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 4 AMINOPYRIDINE; CALCINEURIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; PROTEIN KINASE D; PROTEIN KINASE INHIBITOR; SEROTONIN;

DRUG ACTIVITY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE REPRESSION; HEART FAILURE; HEART HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 14644431730     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24144     Document Type: Review

References (72)

1. Linseman, J.V., and Bristow, M.R. 2003. Drug therapy and heart failure prevention. Circulation. 107:1234-1236.
2. Vakili, B.A., Okin, P.M., and Devereux, R.B. 2001. Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141:334-341.
3. Okin, P.M., et al.; for the LIFE Study Investigators. 2004. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292:2343-2349.
4. Devereux, R.B., et al. 2004. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292:2350-2356.
5. Gardin, J.M., and Lauer, M.S. 2004. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 292:2396-2398.
6. Olson, E.N., and Schneider, M.D. 2003. Sizing up rhe heart: development redux in disease. Genes Dev. 17:1937-1956.
7. Chien, K.R. 1999. Stress pathways and heart failure. Cell. 98:555-558.
8. Marks, A.R. 2003. A guide for the perplexed: towards an understanding of the molecular basis of heart failure. Circulation. 107:1456-1459.
9. Molkentin, J.D., and Dorn, I.G., 2nd. 2001. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63:391-426.
10. Abraham, W.T., et al. 2002. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol. Med. 8:750-760.
11. Lowes, B.D., et al. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl J. Med. 346:1357-1365.
12. Blaxall, B.C., Tschannen-Moran, B.M., Milano, C.A., and Koch, W.J. 2003. Differential gene expression and genomic patient stratification following left ventricular assist device support. J. Am. Coll. Cardiol. 41:1096-1106.
13. McKinsey, T.A., and Olson, E.N. 2004. Cardiac histone acetylation - therapeutic opportunities abound. Trends Genet. 20:206-213.
14. Braunwald, E., and Bristow, M.R. 2000. Congestive heart failure: fifty years of progress. Circulation. 102(Suppl. 4):IV14-IV23.
15. Herron, T.J., and McDonald, K.S. 2002. Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ. Res. 90:1150-1152.
16. Nakao, K., Minobe, W., Roden, R., Bristow, M.R., and Leinwand, L.A. 1997. Myosin heavy chain gene expression in human heart failure. J. Clin. Invest. 100:2362-2370.
17. Miyata, S., Minobe, W., Bristow, M.R., and Leinwand, L.A. 2000. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86:386-390.
18. Niimura, H., et al. 2002. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 105:446-451.
19. Ashrafian, H., Redwood, C., Blair, E., and Watkins, H. 2003. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 19:263-268.
20. Sano, M., et al. 2002. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat. Med. 8:1310-1317.
21. Sugden, P.H., and Clerk, A. 1998. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83:345-352.
22. Frey, N., and Olson, E.N. 2003. Cardiac hypertrophy: the good, the bad, and the ugly Annu. Rev. Physiol. 65:45-79.
23. Rockman, H.A., Koch, W.J., and Lefkowitz, R.J. 2002. Seven-transmembrane- spanning receptors and heart function. Nature. 415:206-212.
24. Fischle, W., Wang, Y., and Allis, C.D. 2003. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15:172-183.
25. Verdin, E., Dequiedt, F., and Kasler, H.G. 2003. Class II histone deacetylases: versatile regulators. Trends Genet. 19:286-293.
26. Zhang, C.L., et al. 2002. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:479-488.
27. Bush, E., et al. 2004. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 101:2870-2875.
28. Vega, R.B., et al. 2004. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 24:8374-8385.
29. Chang, S., et al. 2004. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart. Mol. Cell. Biol. 24:8467-8476.
30. McKinsey, T.A., Zhang, C.L., and Olson, E.N. 2002. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27:40-47.
31. Harrison, B.C., et al. 2004. The CRM1 nuclear export receptor controls of pathological cardiac gene expression. Mol. Cell. Biol. 24:10636-10649.
32. Youn, H.D., Grozinger, C.M., and Liu, J.O. 2000. Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4. J. Biol. Chem. 275:22563-22567.
33. Han, A., et al. 2003. Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2. Nature. 422:730-734.
34. McKinsey, T.A., Zhang, C.L., Lu, J., and Olson, E.N. 2000. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 408:106-111.
35. McKinsey, T.A., Zhang, C.L., and Olson, E.N. 2000. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl. Acad. Sci. U. S. A. 97:14400-14405.
36. Grozinger, C.M., and Schreiber, S.L. 2000. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. U. S. A. 97:7835-7840.
37. McKinsey, T.A., Zhang, C.L., and Olson, E.N. 2001. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol. Cell. Biol. 21:6312-6321.
38. Wang, A.H., and Yang, X.J. 2001. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol. Cell. Biol. 21:5992-6005.
39. Das, D.K. 2003. Protein kinase C isozymes signaling in the heart. J. Mol. Cell. Cardiol. 35:887-889.
40. Force, T., Kuida, K., Namchuk, M., Parang, K., and Kyriakis, J.M. 2004. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation. 109:1196-1205.
41. Gschwendt, M., et al. 1996. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 392:77-80.
42. Haworth, R.S., et al. 2004. Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function. Circ Res. 95:1091-1099.
43. Van Lint, J., et al. 2002. Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol. 12:193-200.
44. Han, J., and Molkentin, J.D. 2000. Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends Cardiovasc. Med. 10:19-22.
45. Youn, H.D., Chatila, T.A., and Liu, J.O. 2000. Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J. 19:4323-4231.
46. Naya, F.J., et al. 2002. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat. Med. 8:1303-1309.
47. Wang, L., Fan, C., Topol, S.E., Topol, E.J., and Wang, Q. 2003. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 302:1578-1581.
48. Czubryt, M.P., McAnally, J., Fishman, G.I., and Olson, E.N. 2003. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc. Natl. Acad. Sci. U. S. A. 100:1711-1716.
49. Sano, M., et al. 2004. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J. 23:3559-3569.
50. Molkentin, J.D., et al. 1998. A calcineurin-dependent transcripdonal pathway forcatdiac hypertrophy. Cell. 93:215-228.
51. Leinwand, L.A. 2001. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc. Natl. Acad. Sci. U. S. A. 98:2947-2949.
52. Antos, C.L., et al. 2002. Activated glycogen synthase kinase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 99:907-912.
53. Haq, S., et al. 2000. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151:117-130.
54. Morisco, C., et al. 2000. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J. Biol. Chem. 275:14466-14475.
55. Frey, N., Katus, H.A., Olson, E.N., and Hill, J.A. 2004. Hypertrophy of the heart: a new therapeutic target? Circulation. 109:1580-1589.
56. Vega, R.B, Bassel-Duby, R., and Olson, E.N. 2003. Control of cardiac growth and function by calcineurin signaling. J. Biol. Chem. 278:36981-36984.
57. Yang, J., et al. 2000. Independent signals control expression of the Calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ. Res. 87:E61-E68.
58. Vega, R.B., et al. 2003. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100:669-674.
59. Rothermel, B.A., et al. 2001. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:3328-3333.
60. Hill, J.A., et al. 2002. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J. Biol. Chem. 277:10251-10255.
61. van Rooij, E., et al. 2004. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ. Res. 94:e18-e26.
62. Nebigil, C.G., et al. 2003. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation. 107:3223-3229.
63. Nebigil, C.G., et al. 2001. Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation. 103:2973-2979.
64. Lau, O.D., et al. 2000. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell. 5:589-595.
65. Balasubramanyam, K., Swaminathan, V., Ranganathan, A., and Kundu, T.K. 2003. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278:19134-19140
66. Piekarz, R., and Bates, S. 2004. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 10:2289-2298.
67. Yanazume, T., et al. 2003. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 23:3593-3606.
68. Antos, C.L., et al. 2003. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278:28930-28937.
69. Kook, H., et al. 2003. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 112:863-871. doi:10.1172/JCI200319137
70. Chang, H.M., et al. 2004. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. U. S. A. 101:9578-9583.
71. Westermann, S., and Weber, K. 2003. Post-translational modifications regulate microtubule function. Nat. Rev. Mol. Cell Biol. 4:938-947.
72. Davis, F.J., Pillai, J.B., Gupta, M., and Gupta, M.P. 2005. Concurrent opposite effects of an inhibitor of histone deacetylases, Trichostatin-A, on the expression of cardiac {alpha}-myosin heavy chain and tubulins: implication for gain in cardiac muscle contractility. Am. J. Physiol. Heart Circ. Physiol. 288:H1477-H1490.